Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360º synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rise in prevalence of chronic disease
3.2.1.2 Technological advancement in immunoassay interference blocker
3.2.1.3 Increase in demand for high accurate diagnostic devices
3.2.1.4 Rising demand for biochemical testing
3.2.2 Industry pitfalls & challenges
3.2.2.1 High manufacturing cost of blocker
3.2.2.2 Lack of awareness about the importance of interference blockers
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Antibody interference blocker
5.2.1 Human serum derived
5.2.2 Animal serum derived
5.2.3 Human immunoglobulin blocker
5.2.4 Animal polyclonal antibody
5.2.5 Heterophilic blocking agent
5.3 Detection interference blocker
5.3.1 Enzyme blocker
5.3.2 Beta-galactosidase blocker
5.3.3 Alkaline phosphate blocker
5.4 Surface interference
5.4.1 Poly BSA blocker
5.4.2 Bovine serum albumin blocker
5.4.3 BSA fraction V blocker
5.4.4 Blocking buffer
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Sandwich immunoassay
6.3 Competitive ELISA
6.4 Other applications
Chapter 7 Market Estimates and Forecast, By Technology, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 ELISA
7.3 Chemiluminescence immunoassays
7.4 Fluorescence immunoassays
7.5 Latex agglutination
7.6 Other technologies
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Biotechnology companies
8.3 Contract research organizations
8.4 Academic & research institutes
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Meridian Bioscience
10.2 F. Hoffmann La Roche Ltd.
10.3 Candor Bioscience GmbH
10.4 Nordic Biosite
10.5 Bio-Rad Laboratories Inc.
10.6 Aviva Biosystem Biology Corporation
10.7 Scantibodies Laboratory Inc.
10.8 Rockland Immunochemicals Inc.
10.9 Abcam PLC
10.10 Thermo Fisher Scientific Inc.
10.11 Surmodic IVD Inc.
10.12 Electron Microscopy Science
10.13 Merck KGaA
10.14 Jackson ImmunoResearch Inc.
